Cargando…

Long-Term Outcomes of the PRESERFLO MicroShunt Implant in a Heterogeneous Glaucoma Cohort

The Preserflo MicroShunt represents a novel glaucoma treatment device, necessitating long-term follow-up data to accurately assess its efficacy. The aim of this study is to report real-world data of a heterogenous glaucoma cohort who received Preserflo implantation at a specialized glaucoma clinic....

Descripción completa

Detalles Bibliográficos
Autores principales: Storp, Jens Julian, Vietmeier, Friederike Elisabeth, Merté, Ralph-Laurent, Koch, Raphael, Zimmermann, Julian Alexander, Eter, Nicole, Brücher, Viktoria Constanze
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342323/
https://www.ncbi.nlm.nih.gov/pubmed/37445509
http://dx.doi.org/10.3390/jcm12134474
_version_ 1785072471588732928
author Storp, Jens Julian
Vietmeier, Friederike Elisabeth
Merté, Ralph-Laurent
Koch, Raphael
Zimmermann, Julian Alexander
Eter, Nicole
Brücher, Viktoria Constanze
author_facet Storp, Jens Julian
Vietmeier, Friederike Elisabeth
Merté, Ralph-Laurent
Koch, Raphael
Zimmermann, Julian Alexander
Eter, Nicole
Brücher, Viktoria Constanze
author_sort Storp, Jens Julian
collection PubMed
description The Preserflo MicroShunt represents a novel glaucoma treatment device, necessitating long-term follow-up data to accurately assess its efficacy. The aim of this study is to report real-world data of a heterogenous glaucoma cohort who received Preserflo implantation at a specialized glaucoma clinic. A total of 160 eyes of 160 patients who underwent Preserflo MicroShunt implantation were retrospectively enrolled in this study. Patient characteristics, as well as success and failure rates, were assessed. The numbers of adverse events and revision procedures were recorded, along with any reduction in supplementary medication. The progression of intraocular pressure (IOP) was assessed over the course of 12 months, and fluctuations were analyzed. The overall success rate was 61.9% (complete success: 51.3%, qualified success: 10.6%). Revision surgery was performed in 25% of cases. Excessive hypotony occurred postoperatively in 54.4% of patients and regressed after 7 days in 88.8% of all cases. Median IOP decreased from 22 (interquartile range (IQR): 17–27) mmHg preoperatively to 14 (IQR 12–16) mmHg at 12 months postoperatively (p < 0.01). The median number of antiglaucomatous agents decreased from three to zero at latest follow-up. The Preserflo MicroShunt achieved a noticeable reduction in IOP over the course of 12 months in glaucoma patients, irrespective of disease severity or disease subtype. The frequency of postoperative adverse events and number for revision surgeries over the course of the follow-up period were low.
format Online
Article
Text
id pubmed-10342323
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103423232023-07-14 Long-Term Outcomes of the PRESERFLO MicroShunt Implant in a Heterogeneous Glaucoma Cohort Storp, Jens Julian Vietmeier, Friederike Elisabeth Merté, Ralph-Laurent Koch, Raphael Zimmermann, Julian Alexander Eter, Nicole Brücher, Viktoria Constanze J Clin Med Article The Preserflo MicroShunt represents a novel glaucoma treatment device, necessitating long-term follow-up data to accurately assess its efficacy. The aim of this study is to report real-world data of a heterogenous glaucoma cohort who received Preserflo implantation at a specialized glaucoma clinic. A total of 160 eyes of 160 patients who underwent Preserflo MicroShunt implantation were retrospectively enrolled in this study. Patient characteristics, as well as success and failure rates, were assessed. The numbers of adverse events and revision procedures were recorded, along with any reduction in supplementary medication. The progression of intraocular pressure (IOP) was assessed over the course of 12 months, and fluctuations were analyzed. The overall success rate was 61.9% (complete success: 51.3%, qualified success: 10.6%). Revision surgery was performed in 25% of cases. Excessive hypotony occurred postoperatively in 54.4% of patients and regressed after 7 days in 88.8% of all cases. Median IOP decreased from 22 (interquartile range (IQR): 17–27) mmHg preoperatively to 14 (IQR 12–16) mmHg at 12 months postoperatively (p < 0.01). The median number of antiglaucomatous agents decreased from three to zero at latest follow-up. The Preserflo MicroShunt achieved a noticeable reduction in IOP over the course of 12 months in glaucoma patients, irrespective of disease severity or disease subtype. The frequency of postoperative adverse events and number for revision surgeries over the course of the follow-up period were low. MDPI 2023-07-04 /pmc/articles/PMC10342323/ /pubmed/37445509 http://dx.doi.org/10.3390/jcm12134474 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Storp, Jens Julian
Vietmeier, Friederike Elisabeth
Merté, Ralph-Laurent
Koch, Raphael
Zimmermann, Julian Alexander
Eter, Nicole
Brücher, Viktoria Constanze
Long-Term Outcomes of the PRESERFLO MicroShunt Implant in a Heterogeneous Glaucoma Cohort
title Long-Term Outcomes of the PRESERFLO MicroShunt Implant in a Heterogeneous Glaucoma Cohort
title_full Long-Term Outcomes of the PRESERFLO MicroShunt Implant in a Heterogeneous Glaucoma Cohort
title_fullStr Long-Term Outcomes of the PRESERFLO MicroShunt Implant in a Heterogeneous Glaucoma Cohort
title_full_unstemmed Long-Term Outcomes of the PRESERFLO MicroShunt Implant in a Heterogeneous Glaucoma Cohort
title_short Long-Term Outcomes of the PRESERFLO MicroShunt Implant in a Heterogeneous Glaucoma Cohort
title_sort long-term outcomes of the preserflo microshunt implant in a heterogeneous glaucoma cohort
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342323/
https://www.ncbi.nlm.nih.gov/pubmed/37445509
http://dx.doi.org/10.3390/jcm12134474
work_keys_str_mv AT storpjensjulian longtermoutcomesofthepreserflomicroshuntimplantinaheterogeneousglaucomacohort
AT vietmeierfriederikeelisabeth longtermoutcomesofthepreserflomicroshuntimplantinaheterogeneousglaucomacohort
AT merteralphlaurent longtermoutcomesofthepreserflomicroshuntimplantinaheterogeneousglaucomacohort
AT kochraphael longtermoutcomesofthepreserflomicroshuntimplantinaheterogeneousglaucomacohort
AT zimmermannjulianalexander longtermoutcomesofthepreserflomicroshuntimplantinaheterogeneousglaucomacohort
AT eternicole longtermoutcomesofthepreserflomicroshuntimplantinaheterogeneousglaucomacohort
AT brucherviktoriaconstanze longtermoutcomesofthepreserflomicroshuntimplantinaheterogeneousglaucomacohort